CoChat
Sign Up
Cited by 317Phytochemicals and Antioxidant ActivitiesBlood Pressure and Hypertension StudiesBotanical Studies and Applications

Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Open access
Serban, Maria‐Corina, Sahebkar, Amirhossein, Zanchetti, Alberto, Mikhailidis, Dimitri P., Howard, George, Antal, Diana, Andrica, Florina, Ahmed, Ali +8 more·2016·Journal of the American Heart Association
DOI 10.1161/jaha.115.002713PMC PMC5015358
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Quercetin, the most abundant dietary flavonol, has antioxidant effects in cardiovascular disease, but the evidence regarding its effects on blood pressure ( BP ) has not been conclusive. We assessed the impact of quercetin on BP through a systematic review and meta‐analysis of available randomized controlled trials. Methods and Results: We searched PUBMED , Cochrane Library, Scopus, and EMBASE up to January 31, 2015 to identify placebo‐controlled randomized controlled trials investigating the effect of quercetin on BP . Meta‐analysis was performed using either a fixed‐effects or random‐effect model according to I 2 statistic. Effect size was expressed as weighted mean difference ( WMD ) and 95% CI . Overall, the impact of quercetin on BP was reported in 7 trials comprising 9 treatment arms (587 patients). The results of the meta‐analysis showed significant reductions both in systolic BP ( WMD : −3.04 mm Hg, 95% CI : −5.75, −0.33, P =0.028) and diastolic BP ( WMD : −2.63 mm Hg, 95% CI : −3.26, −2.01, P <0.001) following supplementation with quercetin. When the studies were categorized according to the quercetin dose, there was a significant systolic BP and diastolic BP ‐reducing effect in randomized controlled trials with doses ≥500 mg/day ( WMD : −4.45 mm Hg, 95% CI : −7.70, −1.21, P =0.007 and −2.98 mm Hg, 95% CI : −3.64, −2.31, P <0.001, respectively), and lack of a significant effect for doses <500 mg/day ( WMD : −1.59 mm Hg, 95% CI : −4.44, 1.25, P =0.273 and −0.24 mm Hg, 95% CI : −2.00, 1.52, P =0.788, respectively), but indirect comparison tests failed to significant differences between doses. Conclusions: The results of the meta‐analysis showed a statistically significant effect of quercetin supplementation in the reduction of BP , possibly limited to, or greater with dosages of >500 mg/day. Further studies are necessary to investigate the clinical relevance of these results and the possibility of quercetin application as an add‐on to antihypertensive therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.115.002713

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Others have found cardiometabolic improvement effects of anthocyanin, catechin, curcumin, flavanol, genistein, and quercetin.

    “Others have also found cardiometabolic improvement effects of anthocyanin,32 catechin,33,34 curcumin,35 flavanol,36 genistein,37 and quercetin.38,39”

    From Micronutrient Supplementation to Reduce Cardiovascular Risk (2022) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 58 · Cited by 317

Research works printed but not linked: 55

  1. [1]Balentine DA, Dwyer JT, Erdman JW, Ferruzzi MG, Gaine PC, Harnly JM, Kwik‐Uribe CL. Recommendations on reporting requirements for flavonoids in research. Am J Clin Nutr. 2015; 101: 1113– 1125. 25854881
  2. [2]Serban C, Sahebkar A, Ursoniu S, Andrica F, Banach M. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta‐analysis of randomized controlled trials. J Hypertens. 2015; 33: 1119– 1127. 25875025
  3. [3]Ursoniu S, Sahebkar A, Andrica F, Serban C, Banach M. Effects of flaxseed supplements on blood pressure: a systematic review and meta‐analysis of controlled clinical trial. Clin Nutr. 2016; 35: 615– 625. 26071633
  4. [4]Banach M, Aronow WS, Serban MC, Sahebkar A, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015; 95‐96c: 111– 125. 25819754
  5. [5]Lairon D, Amiot MJ. Flavonoids in food and natural antioxidants in wine. Curr Opin Lipidol. 1999; 10: 23– 28. 10095986
  6. [6]Hertog MG, Feskens EJ, Kromhout D, Hollman P, Katan M. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993; 342: 1007– 1011. 8105262
  7. [7]Kelly GS. Quercetin. Monograph. Altern Med Rev. 2011; 16: 172– 194. 21649459
  8. [8]Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res. 2004; 24: 851– 874.
  9. [9]Perez‐Vizcaino F, Duarte J, Santos‐Buelga C. The flavonoid paradox: conjugation and deconjugation as key steps for the biological activity of flavonoids. J Sci Food Agric. 2012; 92: 1822– 1825. 22555950
  10. [10]Men K, Duan X, Wei XW, Gou ML, Huang MJ, Chen LJ, Qian ZY, Wei YQ. Nanoparticle‐delivered quercetin for cancer therapy. Anticancer Agents Med Chem. 2014; 14: 826– 832. 24851877
  11. [11]Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R, Palumbo R. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res. 2014; 159: 185– 205. 24114481
  12. [12]Hubbard G, Stevens J, Cicmil M, Sage T, Jordan P, Williams C, Lovegrove J, Gibbins J. Quercetin inhibits collagen‐stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost. 2003; 1: 1079– 1088. 12871380
  13. [13]Chirumbolo S. Quercetin as a potential anti‐allergic drug: which perspectives? Iran J Allergy Asthma Immunol. 2011; 10: 139– 140. 21625024
  14. [14]Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014; 109: 8– 14. 24946265
  15. [15]Nabavi SF, Russo GL, Daglia M, Nabavi SM. Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem. 2015; 179C: 305– 310. 25722169
  16. [16]Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets. 2010; 9: 263– 285. 20887269
  17. [17]Pan H‐C, Jiang Q, Yu Y, Mei J‐P, Cui Y‐K, Zhao W‐J. Quercetin promotes cell apoptosis and inhibits the expression of MMP‐9 and fibronectin via the AKT and ERK signalling pathways in human glioma cells. Neurochem Int. 2015; 80: 60– 71. 25481090
  18. [18]Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti‐inflammatory, anti‐proliferative and anti‐atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011; 218: 44– 52. 21601209
  19. [19]Duarte J, Pérez‐Palencia R, Vargas F, Angeles Ocete M, Pérez‐Vizcaino F, Zarzuelo A, Tamargo J. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol. 2001; 133: 117– 124. 11325801 PMC1572775
  20. [20]Gao H, Chen C, Huang S, Li B. Quercetin attenuates the progression of monocrotaline‐induced pulmonary hypertension in rats. J Biomed Res. 2012; 26: 98– 102. 23554737 PMC3597325
  21. [21]Garcia‐Saura MF, Galisteo M, Villar IC, Bermejo A, Zarzuelo A, Vargas F, Duarte J. Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem. 2005; 270: 147– 155. 15792364
  22. [22]Mackraj I, Govender T, Ramesar S. The antihypertensive effects of quercetin in a salt‐sensitive model of hypertension. J Cardiovasc Pharmacol. 2008; 51: 239– 245. 18356687
  23. [23]Montenegro MF, Neto‐Neves EM, Dias‐Junior CA, Ceron CS, Castro MM, Gomes VA, Kanashiro A, Tanus‐Santos JE. Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2010; 382: 293– 301. 20694791
  24. [24]Morales‐Cano D, Menendez C, Moreno E, Moral‐Sanz J, Barreira B, Galindo P, Pandolfi R, Jimenez R, Moreno L, Cogolludo A, Duarte J, Perez‐Vizcaino F. The flavonoid quercetin reverses pulmonary hypertension in rats. PLoS One. 2014; 9: e114492. 25460361 PMC4252144
  25. [25]Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008; 585: 325– 337. 18417116
  26. [26]Islam MA, Schmidt RW, Gunaseelan S, Sanchez A. An update on the cardiovascular effects of quercetin, a plant flavonoid. Curr Nutr Food Sci. 2014; 10: 36– 48.
  27. [28]Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta‐Analysis Version 2. Englewood, NJ: Biostat; 2005: 104.
  28. [29]Song F, Altman DG, Glenny A‐M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ. 2003; 326: 472. 12609941 PMC150178
  29. [30]Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50: 683– 691. 9250266
  30. [32]Javadi F, Eghtesadi S, Ahmadzadeh A, Aryaeian N, Zabihiyeganeh M, Foroushani AR, Jazayeri S. The effect of quercetin on plasma oxidative status, C‐reactive protein and blood pressure in women with rheumatoid arthritis. Int J Prev Med. 2014; 5: 293. 24829713 PMC4018638
  31. [33]Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double‐blind randomized controlled clinical trial. Int J Prev Med. 2013; 4: 777. 24049596 PMC3775217
  32. [34]Conquer J, Maiani G, Azzini E, Raguzzini A, Holub B. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr. 1998; 128: 593– 597. 9482769
  33. [35]Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007; 137: 2405– 2411. 17951477
  34. [36]Egert S, Bosy‐Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta‐Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G. Quercetin reduces systolic blood pressure and plasma oxidised low‐density lipoprotein concentrations in overweight subjects with a high‐cardiovascular disease risk phenotype: a double‐blinded, placebo‐controlled cross‐over study. Br J Nutr. 2009; 102: 1065– 1074. 19402938
  35. [37]Lee K‐H, Park E, Lee H‐J, Kim M‐O, Cha Y‐J, Kim J‐M, Lee H, Shin M‐J. Effects of daily quercetin‐rich supplementation on cardiometabolic risks in male smokers. Nutr Res Pract. 2011; 5: 28– 33. 21487493 PMC3061266
  36. [38]Pfeuffer M, Auinger A, Bley U, Kraus‐Stojanowic I, Laue C, Winkler P, Rüfer C, Frank J, Bösch‐Saadatmandi C, Rimbach G. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr Metab Cardiovasc Dis. 2013; 23: 403– 409. 22118955
  37. [39]Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A. Quercetin protects against diabetes‐induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS One. 2013; 8: e63784. 23717483 PMC3661670
  38. [40]Larson AJ, Symons JD, Jalili T. Quercetin: a treatment for hypertension?—a review of efficacy and mechanisms. Pharmaceuticals. 2010; 3: 237– 250. PMC3991028 27713250
  39. [41]Larson AJ, Symons JD, Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr. 2012; 3: 39– 46. 22332099 PMC3262612
  40. [42]Häckl L, Cuttle G, Dovichi S, Lima‐Landman M, Nicolau M. Inhibition of angiotensin‐converting enzyme by quercetin alters the vascular response to bradykinin and angiotensin I. Pharmacology. 2002; 65: 182– 186. 12174832
  41. [43]Yamamoto Y, Oue E. Antihypertensive effect of quercetin in rats fed with a high‐fat high‐sucrose diet. Biosci Biotechnol Biochem. 2006; 70: 933– 939. 16636461
  42. [44]Nicholson SK, Tucker GA, Brameld JM. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc Nutr Soc. 2008; 67: 42– 47. 18234130
  43. [45]Sanchez M, Galisteo M, Vera R, Villar IC, Zarzuelo A, Tamargo J, Pérez‐Vizcaíno F, Duarte J. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens. 2006; 24: 75– 84. 16331104
  44. [46]Sahebkar A, Serban MC, Gluba‐Brzózka A, Mikhailidis DP, Cicero AF, Rysz J, Banach M. Lipid‐modifying effects of nutraceuticals: An evidence‐based approach. Nutrition 2016; doi: 10.1016/j.nut.2016.04.007. 27324061 · DOI
  45. [48]Cao J, Zhang Y, Chen W, Zhao X. The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. Br J Nutr. 2010; 103: 249– 255. 19747418
  46. [49]Lee‐Hilz YY, Stolaki M, van Berkel WJ, Aarts JM, Rietjens IM. Activation of EpRE‐mediated gene transcription by quercetin glucuronides depends on their deconjugation. Food Chem Toxicol. 2008; 46: 2128– 2134. 18375031
  47. [50]Egert S, Boesch‐Saadatmandi C, Wolffram S, Rimbach G, Müller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr. 2010; 140: 278– 284. 20032478
  48. [51]Shimoi K, Saka N, Nozawa R, Sato M, Amano I, Nakayama T, Kinae N. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos. 2001; 29: 1521– 1524. 11717168
  49. [52]McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012; 95: 454– 464. 22218162 PMC3260072
  50. [53]Vogiatzoglou A, Mulligan AA, Lentjes MA, Luben RN, Spencer JP, Schroeter H, Khaw KT, Kuhnle GG. Flavonoid intake in European adults (18 to 64 years). PLoS One. 2015; 10: e0128132. 26010916 PMC4444122
  51. [54]Harwood M, Danielewska‐Nikiel B, Borzelleca J, Flamm G, Williams G, Lines T. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007; 45: 2179– 2205. 17698276
  52. [55]EFSA panel on dietetic products, nutrition and allergies (NDA). Scientific opinion on the substantiation of health claims related to quercetin and protection of DNA, proteins and lipids from oxidative damage (ID 1647), “cardiovascular system” (ID 1844), “mental state and performance” (ID 1845), and “liver, kidneys” (ID 1846) pursuant to article 13(1) of regulation (EC) no 1924/2006. EFSA J. 2011; 9: 2067 [2015 pp.]
  53. [56]Peluso I, Palmery M. Flavonoids at the pharma‐nutrition interface: is a therapeutic index in demand? Biomed Pharmacother. 2015; 71: 102– 107. 25960223
  54. [57]Michalska M, Gluba A, Mikhailidis DP, Nowak P, Bielecka‐Dabrowa A, Rysz J, Banach M. The role of polyphenols in cardiovascular disease. Med Sci Monit. 2010; 16: RA110– RA119. 20424562
  55. [58]Hodek P, Trefil P, Stiborová M. Flavonoids—potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact. 2002; 139: 1– 21. 11803026

Authors
Serban, M., Sahebkar, A., Zanchetti, A., Mikhailidis, D. P., Howard, G., Antal, D., Andrica, F., Ahmed, A., Aronow, W. S., Muntner, P., Lip, G. Y. H., Graham, I., Wong, N., Rysz, J., Banach, M., & for the Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group
Affiliations
  • University of Alabama at Birmingham, AL
  • Mashhad University of Medical Sciences (IR)
  • University of Milan (IT)
  • The Royal Free Hospital (GB)
  • University of Alabama at Birmingham (US)
  • Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
  • Veterans Health Administration (US)
  • New York Medical College (US)
  • Birmingham City Hospital (GB)
  • Erasmus MC (NL)
  • University of California, Irvine (US)
  • Medical University of Lodz (PL)
Corresponding author
Banach, Maciej
ORCID
Venue
Journal of the American Heart Association
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-07-06
Volume
5
Issue
7
ISSN
2047-9980 (ISSN-L)
DOI
10.1161/jaha.115.002713
PMC
PMC5015358
OpenAlex
W2467895334
Cited by
317
References
58
Citations by year
2026: 22 · 2025: 22 · 2024: 33 · 2023: 49 · 2022: 32 · 2021: 46 · 2020: 42 · 2019: 35 · 2018: 15 · 2017: 15 · 2016: 6
FWCI
2.21
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of the American Heart Association (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Touro Scholar (Touro College) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Botanical Studies and Applications
Keywords
quercetin, blood pressure, systolic blood pressure, diastolic blood pressure, flavonoids, dietary supplementation, hypertension, antioxidant activity, dose-response relationship, cardiovascular disease prevention, treatment effect heterogeneity
MeSH terms
Antioxidants, Blood Pressure, Humans, Quercetin, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review